HC Wainwright Forecasts Strong Price Appreciation for Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price target lifted by equities researchers at HC Wainwright from $2.00 to $6.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 80.72% from the company’s previous close.

Several other research firms have also recently weighed in on APTO. StockNews.com initiated coverage on shares of Aptose Biosciences in a research report on Thursday. They issued a “sell” rating for the company. Alliance Global Partners upgraded Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.00.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $3.32 on Friday. The stock’s 50 day simple moving average is $4.57 and its 200 day simple moving average is $7.52. Aptose Biosciences has a one year low of $2.39 and a one year high of $51.61. The firm has a market cap of $7.11 million, a PE ratio of -1.12 and a beta of 1.14.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP purchased a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.